anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Problem Agitate Solution

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 26,550
Current window 22,411-22,440
Pages 885
Rows per page 30
Arc: Problem Agitate Solutionclear collectionreset all
18 30 60

Arc

22,411-22,440 of 26,550

filter-aware
27
The slide uses a Gantt-style visualization to map clinical trial milestones (First Efficacy Assessment, 6-mo PFS/OS, 12-mo PFS/OS) against calendar quarters from 2023 to 2026.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The chart demonstrates superior efficacy of 23ME-00610 over anti-PD1 in stimulating IFNy across multiple cancer types.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
29
The chart shows statistical significance (p<0.01 and p<0.0001) for the combination therapy.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
30
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
31
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
32
The slide uses a combination of a data table, a biological mechanism diagram, and a summary of clinical validation to support the therapeutic thesis.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide uses a combination of a biological process diagram and a line chart showing tumor cell reduction over time.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
35
The slide uses a process-flow diagram at the bottom to map team expertise to the drug discovery pipeline.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
36
Uses a Venn-like diagram to show genetic overlap between asthma and other conditions (COPD, eczema, neuro-inflammation, urticaria) to drive specific R&D strategies.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
37
Uses a bell curve distribution to illustrate the selection strategy for cases and controls.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
38
The slide uses a table to categorize biological targets by cell type and associated disease indications.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
39
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
01
Slide 1
The slide uses Python-like code snippets as a design element to represent the company's computational drug discovery platform.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
02
Absci | Investor Conference Presentation Deck | 22 slidesAbsci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
03
Absci | Investor Conference Presentation Deck | 22 slidesAbsci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
04
The slide uses a flywheel-style circular process to demonstrate the iterative nature of their drug creation platform.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
05
The slide uses a circular diagram to represent the AI-driven feedback loop between wet-lab data generation and model training.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
06
The slide illustrates a process flow from target antigen to AI-designed antibodies.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The slide uses a circular process diagram to link AI design with wet-lab validation.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
08
The slide uses a linear process flow with icons representing the transformation of biological inputs through AI models.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
09
Absci | Investor Conference Presentation Deck | 22 slidesAbsci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
10
The right side uses a dot-plot style visualization to represent the economic structure of a partnership, moving from R&D funding to commercial royalties.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
11
The slide uses a Venn diagram to categorize partnerships. The 'Internal Asset Pipeline' section includes a small table/chart showing three programs (ABS-101, ABS-201, ABS-301).Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
12
The slide uses a Gantt-style chart to show the progress of three assets (ABS-101, ABS-201, ABS-301) across development stages.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
13
The slide uses a split-screen approach: biological mechanism on the left, market sizing on the right.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
14
Absci | Investor Conference Presentation Deck | 22 slidesAbsci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
15
Uses a before-after framing to show how affinity translates to potency.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
16
The slide uses a before-after structure to demonstrate the superiority of the ABS-101 platform over competitors (RVT-3101, MK-7240).Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
17
The visual shows a 3D protein structure with highlighted binding regions for various antibodies.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit